Archive for the ‘Treatment’ Category

Interstitial Cystitis & Bladder Symptoms in Lyme & Bartonella

https://www.treatlyme.net/guide/interstitial-cystitis-lyme  (Article and video Here)

Updated: 10/13/23

Interstitial Cystitis and Bladder Symptoms

By Dr. Marty Ross

Some patients with Lyme disease and bartonella infection have symptoms similar to those seen in a bladder infection. These symptoms include

  • urge to urinate,
  • bladder pain and pain on urination,
  • bladder cramping, and
  • increased frequency of urination.

When these symptoms occur, a bladder infection should be ruled out by a healthcare provider. When it is ruled out, these symptoms are often the result of a condition called Interstitial Cystitis. Depending on a person’s age and other risk factors, a urologist may need to evaluate the bladder with a fiberoptic scope to assure that cancer is not present and to confirm a diagnosis of Interstitial Cystitis.

In this article I review the ways to support Interstitial Cystitis with natural medicines in a Lyme disease treatment.  (See link for article and video)

______________

For more:

Category:

Bartonella, diet and nutrition, Lyme, Supplements, Treatment

Yet Another “Unique” EM Rash

https://danielcameronmd.com/unique-presentation-em-rash/

A UNIQUE PRESENTATION OF AN EM RASH

unique-EM-rash

The rash, indicative of Lyme disease, does not always present as a classic “bull’s-eye rash,” as this case report demonstrates. A broad spectrum of lesions has been reported in patients with Lyme disease (LD). In fact, one study found only 6% of the lesions in LD patients had the “classic bull’s-eye or ring-within-a-ring pattern.” [1]

By 

In the case report, “A Non-Classical Presentation of Erythema Migrans in a 51-Year-Old Woman With Early Manifestation of Lyme Neuroborreliosis (Bannwarth Syndrome),” Lorquet et al. describe a 51-year-old female who presented with general malaise, headache, neck stiffness, and an expanding rash consistent with Lyme neuroborreliosis.2

The woman reported having a worsening of her symptoms over a 4-day period and a rash which expanded on her upper back but she did not recall any tick bites.

“She stated that [the rash] started as a small area of redness, spreading rapidly,” the authors wrote.

Clinicians suspected she might have cellulitis and prescribed cephalexin and valacyclovir. But her symptoms did not improve.

“The “bull’s-eye” appearance of erythema migrans is not the only cutaneous manifestation of the acute stage of Lyme disease. There can be multiple variations of the rash, as demonstrated in the patient.”

According to the patient, “the rash had gotten larger and more pruritic [itchy] and that her headache had become more severe, also causing severe pain that radiated to the right side of her neck,” the authors wrote.

The erythema migrans (EM) rash covered two-thirds of her back and had a 5 cm crusted plaque in the center. There was a second circular rash that appeared, as well, behind the woman’s right ear.

READ: The many presentations of the Lyme disease rash

Clinicians treated her symptoms with intravenous ondansetron, ketorolac, pantoprazole, and saline. But also empirically treated for Lyme disease with doxycycline.

After Lyme disease testing was positive, the woman was diagnosed with Lyme Neuroborreliosis, also known as Bannwarth syndrome in Europe.

Bannwarth syndrome (BS) is a typical manifestation of early Lyme neuroborreliosis (LNB) in Europe. It is characterized by painful radiculopathy, neuropathy, varying degrees of motor weakness and facial nerve palsy, and cerebrospinal fluid (CSF) lymphocytic pleocytosis.3

“Several weeks later, the patient had made a full recovery and was back to her baseline level of functioning,” the authors wrote.

They point out, “The “bull’s-eye” appearance of erythema migrans is not the only cutaneous manifestation of the acute stage of Lyme disease. There can be multiple variations of the rash, as demonstrated in the patient.”

Related Articles:

Single dose of doxycycline for treatment of tick bite only prevents a Lyme disease rash

Erythema migrans rash doesn’t always have a bull’s-eye appearance

Lyme disease mimics cellulitis skin infection

References:
  1. Schotthoefer A M, Green C B, Dempsey G, et al. (October 25, 2022) The Spectrum of Erythema Migrans in Early Lyme Disease: Can We Improve Its Recognition? Cureus 14(10): e30673. doi:10.7759/cureus.30673
  2. Lorquet JR, Pell R, Adams J, Tak M, Ganti L. A Non-Classical Presentation of Erythema Migrans in a 51-Year-Old Woman With Early Manifestation of Lyme Neuroborreliosis (Bannwarth Syndrome). Cureus. 2023 Jun 4;15(6):e39931. doi: 10.7759/cureus.39931. PMID: 37416051; PMCID: PMC10319937.
  3. Shah A, O’Horo JC, Wilson JW, Granger D, Theel ES. An Unusual Cluster of Neuroinvasive Lyme Disease Cases Presenting With Bannwarth Syndrome in the Midwest United States. Open Forum Infect Dis. 2017 Dec 23;5(1):ofx276. doi: 10.1093/ofid/ofx276. PMID: 29383323; PMCID: PMC5777478.

______________

**Comment**

So many thoughts here.

  • The rash issue has caused frequent, unnecessary delays in diagnosis and treatment as doctors are not properly educated on actual science, but have been fed a CDC-narrative.  Most doctors are unaware that this rash is diagnostic for Lyme disease, and that misdiagnosis can have fatal consequences.
  • Aucott reports that 54% of Lyme disease patients who present without a rash are misdiagnosed.
  • The designation of Bannwarth Syndrome is also confusing and has caused massive misdirection.  The symptoms are nearly synonymous with most cases of Lyme & can cause severe burning, stabbing, biting, or tearing pain & responds poorly to analgesics:
    • radicular pain (100%)
    • sleep disturbances (75.3%)
    • headache (46.8%)
    • fatigue (44.2%)
    • malaise (39%)
    • paresthesia (32.5%)
    • peripheral nerve palsy (36.4%)
    • meningeal signs (19.5%)
    • paresis (7.8%)
  • This case study shows many of the problems that continue on unabated in Lymeland.

Category:

Lyme, research, Testing, Treatment

WHO Ignores its Own Rules & Refuses to Share Finalized IHR Amendments With the Public 4 Months Before the Vote

https://merylnass.substack.com/p/the-who-will-ignore-its-own-rules

The WHO will ignore its own rules and refuse to share the finalized IHR Amendments with the public and member states 4 months before the vote in May 2024: CHD-TV

WHO’s principal legal officer, Steven Solomon, created a legal weasel fig leaf to justify this illegal maneuver, which has been approved–but how? by whom? and is there any recourse for the people?

MERYL NASS
Oct. 10, 2023

The WHO’s press release states what happened in very general terms, so only the already-initiated will understand it. Article 55 of the WHO Constitution requires that amendments to WHO documents be offered to the member states and public 4 months in advance of a vote. The Saudi co-chair said to the public that his Working Group on the IHR amendments may not complete their work by January needed to meet the timeline to be voted on in May 2024. In a choreographed move, he asked Principal Legal Officer Steven Solomon what to do about this. Solomon had already crafted a plan. His plan was to create a specious excuse to ignore the existing rules.

Nobody voted on ignoring them. Nobody said this was okay. It just became a done deal. And here is the WHO press release, saying very little, explaining nothing, just issuing a vague statement that the rules will be ignored and no amendments will be available till (probably) after the vote or consensus process takes place in May.

And here is the show where James Corbett, James Roguski and I discuss what is happening before our eyes, and tell you who really runs the WHO—its private donors.

(See link for more)

________________

**Comment**

Similarly to the FDA, CDC, HHS, NIH, NIAID, AMA, medical journals – etc. always attempting to monopolize medicine, the WHO and other global organizations run by the unelected are in lock-step to destroy freedom as we know it and particularly medical freedom.

If you are unfamiliar with IHR (International Health Regulations), and the Pandemic Treaty, which would make the unelected WHO tyrannical ruler of the world, go here:

For more on the monopolization of medicine:

Category:

Activism, Treatment, vaccines, Viruses

Review: Borrelia Miyamotoi

https://danielcameronmd.com/review-borrelia-miyamotoi/

REVIEW: BORRELIA MIYAMOTOI

borrelia-miyamotoi

Borrelia miyamotoi is an emerging tick-borne illness that is transmitted by the deer tick. The most common symptoms of a B. miyamotoi infection include fever, fatigue, headache, chills, myalgia, arthralgia, and nausea.

By 

In their article, “Human Borrelia miyamotoi Infection in North America,” Burde and colleagues discuss the frequency and location of infection in ticks and people, clinical presentation and complications, diagnosis, treatment, and prevention.

Prevalence of B. miyamotoi

B. miyamotoi-infected ticks have been reported throughout the northeastern, northern Midwestern, and western United States. They’ve also been detected in all Canadian provinces except Newfoundland and Labrador.

The prevalence of Borrelia miyamotoi infections is difficult to determine, since the illness is not nationally reportable in the U.S. but reportable in only a few states including Connecticut, Maine, Massachusetts, Minnesota, New Jersey, Vermont, and Wisconsin. And, confirmation of the diagnosis depends upon laboratory testing, which is not always available.

Furthermore, diagnosis can be challenging. “The discrepancy between diagnosed and undiagnosed infection is probably even greater for B. miyamotoi, a tick-borne disease that lacks an easily identifiable clinical marker, such as the erythema migrans rash, and is less well known by health care workers and the general public,” the authors write.

Transmission

B. miyamotoi can be transmitted to humans through the bite of an infected black-legged (deer) tick. Several studies have found that it may be transmitted through blood transfusions, as well.

The B. miyamotoi pathogen can be transmitted from an infected female tick to her eggs, which may result in some larval ticks harboring the infection and transmitting it to a host. “Other larvae become infected after taking a blood meal on an infected mouse reservoir host, molt to the nymphal stage, and then transmit infection to another mouse or human,” they write.

Symptoms & Treatment

B. miyamotoi symptoms can be non-specific and an individual may appear to have a viral-like illness with fever, chills, headache, myalgia, fatigue, arthralgia, and gastrointestinal complaints, according to the authors.

“The most striking clinical feature of B. miyamotoi is relapsing fever with an initial febrile episode followed by a period of wellness and then one or more additional febrile episodes,” the authors write.

Some studies have found that the “average time between relapses was 9 days with a range of 2 days to 2 weeks.”

However, not all individuals develop relapsing fever. “In the largest case series of B. miyamotoi cases in the US, only 2 of 51 cases (4%) developed relapsing fever.”

READ: Don’t Rely on Relapsing Fever to Diagnose B. miyamotoi 

Treatment of B. miyamotoi disease typically involves using the same antibiotics to treat Lyme disease: doxycycline, tetracycline, erythromycin, penicillin, and ceftriaxone. However, there have been no trials to evaluate the effectiveness of these treatments.

Co-infections worsen disease

Co-infections can worsen the illness. There have been reported cases of B. miyamotoi co-infection with B. burgdorferi and/or Babesia microti.

“Previous studies have found that coinfection of B. burgdorferi with either Babesia microti or with Anaplasma phagocytophilum are often associated with more severe disease compared with that caused by B. burgdorferi infection alone,” the authors write.

Testing for the infection can include blood smear, polymerase chain reaction (PCR), and/or antibody detection.

Authors’ Conclude:

“The possibility of B. miyamotoi infection should be considered in any patient with a febrile illness who resides in or has recently traveled to a region where Lyme disease is endemic, especially during the late spring, summer, or early fall.”

Related Articles:

B. miyamotoi can be transmitted from mother ticks to offspring

Could B. miyamotoi infections explain persistent Lyme disease symptoms?

References:
  1. Burde J, Bloch EM, Kelly JR, Krause PJ. Human Borrelia miyamotoi Infection in North America. Pathogens. 2023 Apr 3;12(4):553. doi: 10.3390/pathogens12040553. PMID: 37111439; PMCID: PMC10145171.

_______________

For more:

Since Borrelia miyamotoi is not a reportable illness to the CDC, no one has any clue about prevalence but reports are coming in continually that it’s highly likely to be a much bigger problem than ‘authorities’ believe.
It was recently discovered that:

Also, Borrelia miyamotoi has been in California ticks for a long time:

https://madisonarealymesupportgroup.com/2018/02/15/b-miyamotoi-in-ca-ticks-for-a-long-time/

The following case shows how you can become infected while traveling:  https://madisonarealymesupportgroup.com/2020/10/24/a-case-of-borrelia-miyamotoi/

Category:

Activism, Borrelia Miyamotoi (Relapsing Fever Group), research, Testing, Ticks, Transmission, Treatment, Uncategorized

ACTION ALERT: The FDA & Legalized Censorship

https://anh-usa.org/fda-launches-lab-test-attack/

FDA Launches Lab Test Attack

By ANH-USAOn 
 

A new proposal from the FDA will compromise your ability to get the personalized medical care you need. Action Alert!

We reported a few months ago that the FDA was planning to propose a new rule to extend its power over laboratory developed tests (LDTs). That proposal was published last week, and, in line with our concerns, it represents a major attack on LDTs that we think will compromise patient health. We cannot allow the agency to regulate these critical tests out of existence. Use the forms below to post an official comment to the public docket.

This rule is the culmination of many years of effort from the FDA to extend its power over LDTs. Like previous attempts, what the FDA is trying to do is regulate LDTs like other medical devices, which means a boatload of additional regulatory requirements and, in many cases, premarket review.

This is a critical threat, as LDTs are crucial tools used in personalized medicine because labs can create custom diagnostic tests for all sorts of health conditions. LDTs are diagnostic tests developed and performed by local labs. They are important tools used by healthcare providers to diagnose and manage a wide range of conditions. They are widely used—thousands of different LDTs are available—and include genetic tests, heavy metal tests, tests for rare conditions, nutritional status tests, and hormone tests. They can be tailored to meet specific patient needs and can be used to respond rapidly to emerging threats like COVID-19. Currently, laboratories have the flexibility to adapt and modify tests based on evolving scientific knowledge and patient requirements. That could all change if this proposed rule goes through.  (See link for more and to take action)

The FDA has a long history of attempting to monopolize testing.  If they control testing, they control the entire narrative.

______________

https://anh-usa.org/ftc-clarifies-how-it-will-censor-supplement-claims/

FDA to Censor Supplement Claims

By ANH-USAOn 

While the FTC appears to have backtracked slightly on its draconian campaign to censor supplement health claims, it is really a classic example of doublespeak.  Action Alert!

The FTC is working to conceal the remarkable truth about the healing and disease-preventing powers of foods and nutrients. This is only good if you’re a drug company looking to sell more expensive drugs for preventable chronic illnesses that often do not work. This censorship keeps you from learning that magnesium can help lower blood pressure, for example, or that chromium can lower blood sugar, or any of the other innumerable benefits that come from natural vitamins, minerals, herbs, and amino acids.

The FTC has been censoring natural product health claims for years, but the latest threat is the December 2022 revision to the agency’s Health Products Compliance guidance coupled with the hundreds of warning letters sent in April this year to producers of supplements, homeopathic medicines, and functional foods. These letters warned companies that if they make claims without proper scientific substantiation (that is, evidence from more than one randomized controlled trial, or RCT), they will face large civil penalties. You can reference our earlier coverage for the details.  

Important excerpt:

The agency is talking out of both sides of its mouth. On the one hand, it says quite clearly in its updated guidance (see below) that most supplement claims will require substantiation by RCTs, and other kinds of evidence will not be sufficient. On the other hand, it’s saying there “may” be some exceptions, but it depends on what experts in the field say. But we know good and well that the “experts” the government consults with are often on the take from Big Pharma or are otherwise critics of the use of natural products as the mainstay in health. Just look at what’s happening with another natural medicine in the government’s crosshairs, compounded bioidentical hormone replacement therapy (cBHRT). The FDA asked an “independent” panel of “experts” at the National Academies of Sciences, Engineering, and Medicine to review the clinical utility of cBHRT, and lo and behold, they concluded that there wasn’t any evidence to support cBHRT because there weren’t RCTs supporting safety and efficacy.

In our view, this “clarification” about possible exceptions to the RCT standard is all a smokescreen from the FTC, perhaps to lure companies into thinking they don’t need RCTs to support a health claim so the agency can bring the hammer down on them later.

(See link for more and to take action)

The FDA also has a long history of attempting to monopolize drugs, hormones, and supplements as well. The agency often completely ignores its scientific advisers and approves dangerous drugs & products – often without sufficient data. Pharmaceutical companies like Biogen (Project Onyx) use back channels to get FDA approval. And a court recently ruled that the FDA exceeded its authority by advising against using ivermectin for COVID. Instead, it dug remdesivir out of the drug grave yard after it failed for Ebola, and approved it for COVID (even babies!) despite being ineffective and toxic.

There were more than 500 deaths in the first year of remdesivir usage, but there have only been 20 deaths in 19 years of ivermectin usage. Nurses have dubbed the drug, “Run, death is near!”

But a world famous toxicologist couldn’t find a SINGLE case of an ivermectin overdose death.

_________________

https://anh-usa.org/legalized-censorship-a-radical-shift-in-regulating-speech/

Legalized Censorship: A Radical Shift in Regulating Speech

By ANH-USAOn 
 

From Joseph Mercola, DO

If you think freedom of speech has gone down the tubes, you haven’t seen the half of it yet. September 19, 2023, the U.K. passed a new law to “regulate” (read, censor) online content. The so-called Online Safety Bill has been described as “one of the most far-reaching attempts by Western democracy to regulate online speech.

Interestingly, the bill has been in the works for the last five years, again proving that online censorship is not something that sprang up in response to COVID.  Governments have been steadily moving in this direction for a long time.

As reported by The New York Times, the bill forces online platforms to “proactively screen for objectionable material and to judge whether it is illegal, rather than requiring them to act only after being alerted to illicit content.”

Of course, we now know that flagging material for removal is how the U.S. government has illegally circumvented constitutional free speech rights for the past few years.

September 8, 2023, the Fifth Circuit Court of Appeals upheld part of the lower court’s injunction, banning the White House, surgeon general, the Centers for Disease Control and Prevention, and the FBI from influencing social media companies to remove “disinformation.”

Unfortunately, the appellate court also reversed, vacated and modified other parts of the original injunction, leaving the door wide open for certain federal agencies to continue their censorship activities.

Importantly, officials from the Cybersecurity and Infrastructure Security Agency (CISA) were excluded, even though CISA has played a major, if not central, role in the government’s censorship of Americans.

 (See link for article)

______________

**Comment**

In case you are unaware: the FDA is not our friend. 

For more:

Category:

Activism, Supplements, Testing, Treatment